Health-Related Quality of Life in Primary Antibody Deficiency
-
Asghar Aghamohammadi
,
Ali Montazeri
,
Hassan Abolhassani
,
Sepideh Saroukhani
,
Sarvenaz Pourjabbar
,
Mahmoud Tavassoli
,
Behzad Darabi
,
Amir Imanzadeh
,
Nima Parvaneh
,
Nima Rezaei
Abstract
Patients with primary antibody deficiencies (PAD) are susceptible to recurrent and chronic infections and a variety of complications. This study was performed to assess quality of life (QoL) of PAD patients who were under long term treatment and regular follow-up.Thirty six adults with proved diagnosis of PAD, who had received regular intravenous immunoglobulin replacement therapy, were enrolled in this study. The QoL of selected PAD patients was measured by Medical Outcomes Study 36-item Short-Form (SF-36) Health Survey questionnaire.
The patients with PAD showed significantly reduced scores in physical component in comparison with healthy age-sex matched control subjects (60.2±20.1 vs. 85.5±4.7, P<0.001). Mental component score was also significantly decreased in the patient's group (59.8±19.5 vs. 72.3±3.4, P=0.002). There was a reverse association between SF-36 scores and number of infections episodes (r=-0.73 P=0.003). The patients with long delay diagnosis showed significantly lower SF-36 scores (r=-0.62, P=0.003).
The patients with PAD who were diagnosed timely and managed appropriately seem to have lower complications and better QoL. However, the patients with severe phenotypes and long delay in diagnosis showed lower QoL, even in medical management.
1.Notarangelo LD, Fischer A, Geha RS, Casanova JL, Chapel H, Conley ME, et al. Primary immunodeficiencies: 2009 update. J Allergy Clin Immunol 2009; 124(6):1161-78.
2. Chapel HM. Consensus on diagnosis and management of primary antibody deficiencies. Consensus Panel for the Diagnosis and Management of Primary Antibody Deficiencies. BMJ 1994; 308(6928):581-5. 3. Rezaei N, Aghamohammadi A, Moin M, Pourpak Z, Movahedi M, Gharagozlou M, et al. Frequency and clinical manifestations of patients with primary immunodeficiency disorders in Iran: update from the Iranian Primary Immunodeficiency Registry. J Clin Immunol 2006; 26(6):519-32.
4. Primary immunodeficiency diseases. Report of an IUIS Scientific Committee. International Union of Quality of life in Primary Antibody Deficiencies Immunological Societies. Clin Exp Immunol 1999; 118 (Suppl 1):1-28.
5. Puck JM. Primary immunodeficiency diseases. Jama 1997; 278(22):1835-41.
6. Aghamohammadi A, Moin M, Farhoudi A, Rezaei N, Pourpak Z, Movahedi M, et al. Efficacy of intravenous immunoglobulin on the prevention of pneumonia in patients with agammaglobulinemia. FEMS Immunol Med Microbiol 2004; 40(2):113-8.
7. Aghamohammadi A, Farhoudi A, Nikzad M, Moin M, Pourpak Z, Rezaei N, et al. Adverse reactions of prophylactic intravenous immunoglobulin infusions in Iranian patients with primary immunodeficiency. Ann Allergy Asthma Immunol 2004; 92(1):60-4.
8. Dashti-Khavidaki S, Aghamohammadi A, Farshadi F, Movahedi M, Parvaneh N, Pouladi N, et al. Adverse reactions of prophylactic intravenous immunoglobulin; a 13-year experience with 3004 infusions in Iranian patients with primary immunodeficiency diseases. J Investig Allergol Clin Immunol 2009; 19(2):139-45.
9. Conley ME, Notarangelo LD, Etzioni A. Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies). Clin Immunol 1999; 93(3):190-7.
10. Sigstad HM, Stray-Pedersen A, Froland SS. Coping, quality of life, and hope in adults with primary antibody deficiencies. Health Qual Life Outcomes 2005; 3:31.
11. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30(6):473-83.
12. Montazeri A, Goshtasebi A, Vahdaninia M, Gandek B.The Short Form Health Survey (SF-36): translation and validation study of the Iranian version. Qual Life Res 2005; 14(3):875-82.
13. Fairclough DL, Peterson HF, Cella D, Bonomi P.Comparison of several model-based methods for analysing incomplete quality of life data in cancer clinical trials. Stat Med 1998; 17(5-7):781-96.
14. Ware JE, Kosinski M. Interpreting SF-36 summary health measures: a response. Qual Life Res 2001; 10(5):405-13.
15. Ware JE, Kosinski M, Bayliss MS, McHorney CA, Rogers WH, Raczek A. Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the Medical Outcomes Study. Med Care 1995; 33(4 Suppl):AS264-79.
16. Aghamohammadi A, Pouladi N, Parvaneh N, Yeganeh M, Movahedi M, Gharagolou M, et al. Mortality and morbidity in common variable immunodeficiency. J Trop Pediatr 2007; 53(1):32-8.
17. Schlenk EA, Erlen JA, Dunbar-Jacob J, McDowell J, Engberg S, Sereika SM, et al. Health-related quality of life in chronic disorders: a comparison across studies using the MOS SF-36. Qual Life Res 1998; 7(1):57-65.
18. McHorney CA, Ware JE, Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993; 31(3):247-63.
19. McHorney CA, Ware JE, Rogers W, Raczek AE, Lu JF.The validity and relative precision of MOS short- and long-form health status scales and Dartmouth COOP charts. Results from the Medical Outcomes Study. Med Care 1992; 30(5 Suppl):MS 253-65.
20. Eades-Perner AM, Gathmann B, Knerr V, Guzman D, Veit D, Kindle G, et al. The European internet-based patient and research database for primary immunodeficiencies: results 2004-06. Clin Exp Immunol 2007; 147(2):306-12.
21. Ware JE, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996; 34(3):220-33.
22. Gardulf A, Nicolay U, Math D, Asensio O, Bernatowska E, Bock A, et al. Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. J Allergy Clin Immunol 2004; 114(4):936-42.
23. Nicolay U, Haag S, Eichmann F, Herget S, Spruck D, Gardulf A. Measuring treatment satisfaction in patients with primary immunodeficiency diseases receiving lifelong immunoglobulin replacement therapy. Qual Life Res 2005; 14(7):1683-91.
| Files | ||
| Issue | Vol 10, No 1 (2011) | |
| Section | Articles | |
| Keywords | ||
| Common Variable Immunodeficiency Primary Antibody Deficiency Quality of Life | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
